NCT04398524 2024-01-16A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPCISA PharmaceuticalsPhase 2 Unknown65 enrolled
NCT03669718 2023-12-29A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPCISA PharmaceuticalsPhase 2 Unknown194 enrolled
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled